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T
he Lasix story is a classic American horseman’s story. Bleeding 
from the nose in racehorses long has been identified by horse-
men as performance-limiting, and nearly all modern Thor-
oughbreds carry the genetic code of Bartlett’s Childers, a son 
of the Darley Arabian born in 1716. The unraced full brother 
of the successful racehorse Flying Childers eclipsed his brother in the breeding 
shed but was unable to race because he bled from the nose—so much so that 
he was often referred to as “Bleeding Childers.” Long before anyone knew why 
racehorses bled from the nose, horsemen have been trying to prevent it.
The late renowned Central Kentucky equine veterinarian Alex Harthill often 
has been credited with the first use of Lasix in racing when he used it in another 
notable horse who is well represented in the genetic background of Thorough-
breds throughout the world—Northern Dancer. Harthill reportedly administered 
Lasix to Northern Dancer prior to the 1964 Kentucky Derby, and the legendary 
racehorse went on to set a Derby record that held until Secretariat broke 
it in 1973. 
In the late 1960s, the use of Lasix became more widespread, and horsemen 
discovered that withholding water enhanced its protective effect. Horsemen, 
understanding the beneficial effects of Lasix for bleeding, lobbied for its use in 
American racing, and by 1995, New York, the last holdout, had approved Lasix 
for use in racing.
Reviewing Lasix in horse racing in 1976 for the National Association of 
State Racing Commissioners, Dr. Al Gabel and his colleagues noted that Lasix 
“helps prevent epistaxis” and that “in many cases it restores normal perfor-
mance of horses which bleed.”
The bottom line is that almost half a century ago American horsemen 
confidently had identified the protective effects of Lasix against pulmonary 
bleeding in racehorses. Horsemen’s insights and scientific progress have slowly 
been confirming this ever since.
Soon after Gabel wrote his review, the fiber-optic endoscope became 
available. The endoscope allowed veterinarians to look into the trachea of 
horses post-race, confirming horsemen’s long-held suspicions. Racing horses 
did indeed bleed into their lungs during racing, so-called occult bleeding, which 
accounts for unexpectedly poor performances that Lasix protected against. An-
other outcome was that pulmonary bleeding in racehorses got a new and more 




















SCIENCE CONFIRMS WHAT AMERICAN HORSEMEN KNEW  
50 YEARS AGO
By Clara Fenger, DVM, PhD, DACVIM; Steve Selway, DVM; and Thomas Tobin, MRCVS, PhD, DABT
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The dilution effect of Lasix was shown to be primarily in effect for the  
first two and a half hours after its intravenous administration, and a number of subsequent 
studies by research groups in Kentucky under Dr. Thomas Tobin and in Pennsylvania  
under Dr. Lawrence Soma confirmed that three hours after Lasix administration,  
the dilution effect is largely over.
An early concern about Lasix was its potential effect on the detection of 
drugs in urine. As a diuretic, Lasix produces a transiently dilute urine, with the 
issue being that the resultant dilution of many drug types and especially drug 
metabolites could be present in the sample. This led to regulatory concerns 
that the use of Lasix would permit the illicit use of drugs that could escape 
detection. 
The industry rapidly addressed this issue. The dilution effect of Lasix was 
shown to be primarily in effect for the first two and a half hours after its intra-
venous administration, and a number of subsequent studies by research groups 
in Kentucky under Dr. Thomas Tobin and in Pennsylvania under Dr. Lawrence 
Soma confirmed that three hours after Lasix administration, the dilution effect 
is largely over. Therefore, as proposed by the American Association of Equine 
Practitioners, the four-hour Lasix rule was validated in the early 1980s in a 
study coordinated by Drs. George Maylin and Rick Sams, clearing the way for 
the approval of Lasix in American racing. At four hours post-administration, the 
intravenous administration of Lasix was determined to not significantly interfere 
with the detection of drugs in urine. This approach was later considerably 
reinforced by inclusion of a 1.010 urinary specific gravity requirement in the 
Lasix rule. 
By the late 1980s, the legal use of Lasix under strict regulatory guide-
lines was in place in most U.S. jurisdictions. Soma and his research group 
in Pennsylvania had previously established that Lasix improved performance 
in documented “bleeders,” but no evidence had yet been provided about the 
performance effect of Lasix on the small percentage of horses that did not 
experience EIPH. The Pennsylvania group then tried to fill that void by evaluating 
the effect of Lasix on racing performance in the absence of EIPH by including 
endoscopy in the research design. 
In 1990, Dr. Corinne Raphel Sweeney and colleagues reported on this 
study, in which they performed endoscopies on horses that raced first without 
Lasix, a second time with Lasix and a third time without Lasix. The research 
group found no effect of Lasix on racing performance among colts and fillies in 
the absence of EIPH, although they found an effect in geldings. Interestingly, 
the improvement in the performance of geldings was observed from the first, 
no-Lasix race to the second Lasix race, but the geldings did not revert to their 
previous form when returning to no Lasix in the third race. Therefore, the change 
in performance in geldings in that study cannot be solely attributed to the 
addition of Lasix. It can be argued that higher numbers may have demonstrated 
a performance-enhancing effect on the fillies and colts as well or, alternatively, 
may have clearly demonstrated that Lasix has no performance-enhancing effect 
at all, outside its ability to normalize performance by mitigating the severity  
of EIPH.
In an attempt to address whether Lasix enhances performance above its 
ability to normalize the performance of an EIPH sufferer, Dr. Warwick Bayly and 
colleagues at Washington State University studied five research horses on a 
treadmill with the results presented at the 2017 American Association of Equine 
Practitioners Convention. The key performance marker in their landmark study 
was oxygen consumption. For the exercise physiologist, oxygen consumption 
is used as a measure of the amount of aerobic work performed by the animal. 
As a rule, the more elite an athlete, the higher its oxygen consumption. Bayly 
and colleagues showed that horses lost, on average, 14 more kilograms (30.9 
pounds) when administered Lasix. They also found that the weight-adjusted 
oxygen consumption improved with the administration of Lasix. In other words, 
each kilogram of the horse was able to use more energy and oxygen, but the 
entire, lighter horse ran the same distance at the same speed. While commonly 
quoted as support that Lasix is inherently performance-enhancing independent 
of its effect on EIPH, this paper is actually strong evidence to the contrary.
The approval of Lasix in New York racing in 1995 further supports the ben-
efit of Lasix in that it “helps prevent epistaxis.” New York had long kept records 
on the incidence of epistaxis, or frank bleeding from the nostrils, during or after 
the race. Review of these figures in 2000 showed that the 1995 approval of 
Lasix in New York racing reduced the incidence of epistaxis by a “greater than 
400 percent decrease,” according to Dr. Anthony Verderosa, the New York Racing 
Association chief examining veterinarian.
Around the same time, a major study by Diane Gross, Paul Morley and 
colleagues looked for an association between Lasix administration and racing 
performance. They analyzed the racing times for all Thoroughbreds that finished 
a race on dirt in the U.S. and Canada between June 28 and July 13, 1997—a 
modest 22,569 in total. Overall, 74 percent of these horses ran on Lasix, and the 
horses on Lasix raced faster, earned more money and were more likely to finish 
in the top three positions. The authors concluded that Lasix use is apparently 
“associated” with superior performance in Thoroughbred racehorses. Given the 
number of horses and the quality of the statistical analysis, it’s a compelling 
study. Of course, the horses were not evaluated endoscopically, so the study 
cannot determine whether the horses had performance enhancement by Lasix or 
simply whether their performance was normalized by the mitigation of EIPH.
The authors of this study were careful to use the word “associated,”  
which also was used by another major study in this arena. In 2005 Dr. Kenneth  
Hinchcliff and co-authors reported a study on the relationship between EIPH 
score and performance in 744 Thoroughbreds running in Melbourne, Australia. 
The results of this study showed that horses with EIPH scores of 1 or less were 
four times as likely to win and three times as likely to be in the 90th percentile 
for higher race earnings than were horses with grade 2 or greater EIPH. The 
authors concluded that EIPH is “associated” with impaired racing performance 
in horses racing in Melbourne. Since no Lasix was used in any of these races, 
the picture gradually comes into focus. 
The critical study that definitively answered the question of whether Lasix 
administration influences the incidence of EIPH was also conducted by Hinch-
cliff and colleagues. The experimental study was performed in 2007 in South 
Africa and involved 167 horses in what is called a cross-over study. Half of the 
horses received saline and the other half received a full clinical dose of Lasix, 
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500 mg IV. Then, seven days later, the study was repeated, with the treatments 
“crossed-over,” i.e., the horses that had received Lasix now received saline and 
the horses that had received saline now received Lasix. This exquisite design 
allows each horse to serve as its own control, showing how each horse and its 
own EIPH severity responded to the administration of Lasix. The outcome of this 
study, published in 2009, was clear: Horses receiving Lasix had a decreased 
incidence and severity of EIPH, fully supporting the almost half-century-old 
opinion of American horsemen. 
In 2014 another study was conducted in South Africa on the effects of EIPH 
on the racing performance of 1,000 Thoroughbreds, with results similar to the 
2005 Australian study. The conclusion was that the “findings provide strong 
corroboration of previous research indicating that the occurrence of EIPH has a 
major impact on the ability of Thoroughbred racehorses to compete successfully 
as elite athletes.”
Note that the authors said “major impact.”
So, long story short, horsemen in the 1960s correctly identified Lasix as 
effectively protecting racing horses against EIPH and its adverse effects on 
racing performance. Their belief in this clinical judgment led to Lasix being 
approved throughout the Americas and most particularly in North America. This, 
in turn, led (eventually) to rigorous scientific evaluation of the actions of Lasix 
on EIPH and racing performance. These studies fully supported the long-stand-
ing clinical opinions and experience of American horsemen with respect to EIPH, 
its effects on horses and racing performance and the protective effect of Lasix, 
as noted by Gabel and his colleagues in 1976.
One last question is “Why were American horsemen so far ahead of the 
scientific community?” The answer is simple: Successful horsemen and their 
veterinarians make far more intuitive, precise and astute evaluations of the 
horses with whom they share their lives as compared to most scientists. 
The basic standard of proof in science is a 95 percent probability that the 
result is correct, while identifying a horse to win the Kentucky Derby, one of 
20,000 or so horses foaled in a year, is a far more discriminating judgment. 
Basically, horsemen applied their solid practical knowledge and experience and 
correctly assessed the protective effects of Lasix on EIPH. Additionally, there are 
at least 30,000 horsemen running horses, and all it took was one to make the 
initial Lasix-EIPH connection and it took off from there. All of the early scientific 
evaluations, however, were with relatively small numbers of horses, some 
on treadmills, and these experiments gave conflicting results at best. It was 
not until Hinchcliff and Morley and Gross began to evaluate serious numbers 
of horses (700 to 1,000) and 20,000-plus racing times that their rigorous, 
large-number evaluations confirmed what horsemen had known all along about 
water withholding, Lasix and what came to be known as EIPH. 
In closing, since the introduction of Lasix in the 1960s, horse racing 
has made substantial progress in understanding EIPH and protecting horses 
against the adverse effects of bleeding. In the late 1970s, availability of the 
fiber-optic endoscope allowed identification of the so-called “occult bleeder,” 
or blood in the trachea post-race, and the syndrome was named EIPH and a 
useful scoring system was developed. Since then, EIPH has been recognized as 
a progressive disease in racehorses, and moderate to severe EIPH is associated 
with reduced racing performance. Then in 2009, scientists, using 167 horses, 
provided high-quality evidence that Lasix is effective in the prevention of EIPH 
and, consistent with this finding, that Lasix administration is associated with 
more reliable and optimal performance in Thoroughbred racehorses. HJ
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